- Drug Pipelines
- October 2020
- 62 Pages
Global
From €3384EUR$3,500USD£2,908GBP
- Report
- May 2023
- 88 Pages
Global
From €3500EUR$3,878USD£3,114GBP
- Report
- July 2022
- 51 Pages
Global
From €3384EUR$3,500USD£2,908GBP
Cosyntropin is a synthetic form of the human hormone adrenocorticotropic hormone (ACTH) used to treat endocrine and metabolic disorders. It is used to diagnose and treat adrenal insufficiency, a condition in which the adrenal glands do not produce enough of the hormone cortisol. It is also used to diagnose and treat Cushing's syndrome, a condition in which the body produces too much cortisol. Cosyntropin is administered as an injection or intravenous infusion.
Cosyntropin is a prescription drug and is available in generic and brand-name formulations. It is marketed by several pharmaceutical companies, including Novartis, Pfizer, and Merck. It is also available in combination with other drugs, such as hydrocortisone and prednisone.
Cosyntropin is an important drug in the treatment of endocrine and metabolic disorders. It is used to diagnose and treat adrenal insufficiency and Cushing's syndrome, and is available in generic and brand-name formulations. Companies that market cosyntropin include Novartis, Pfizer, and Merck. Show Less Read more